Today, a Director at Cel-Sci Corp, Peter Young, exercised options of Cel-Sci Corp (NYSE MKT: CVM) for $4,200.
Following this transaction Peter Young’s holding in the company was increased by 17.53% to a total of $46.18K. Following Peter Young’s last CVM Buy transaction on May 03, 2018, the stock climbed by 0.6%.
See today’s analyst top recommended stocks >>
Based on Cel-Sci Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $132K and GAAP net loss of $4.71 million. In comparison, last year the company earned revenue of $17.18K and had a GAAP net loss of $8.43 million. Currently, Cel-Sci Corp has an average volume of 66.86K.
The insider sentiment on Cel-Sci Corp has been positive according to 26 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).
